Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 27, 2009

Gen-Probe has elected Carl Hull to be the company's new CEO and to serve on the board of directors. Hull, who currently is the company's president and COO, will take on the post in May, after current CEO Henry Nordhoff steps down. Nordhoff, who has been the company's CEO since 1994, will continue to serve as chairman of the board.


Cellumen has named Jack Reynolds to serve on its board of directors. Reynolds previously was senior VP of R&D at Pfizer Global Research and head of worldwide safety sciences and comparative medicine. He was involved in creating the Center for Molecular Safety Sciences at The Hamner Institutes for Health Sciences, where he served as interim director of safety sciences and translational research.

Reynolds also has served on the boards of the Health and Environmental Sciences Institute, the Toxicology Education Foundation, and the Toxicology Forum, and he has worked on other federal boards.


Bruker has tapped Brian Monahan to be chief accounting officer and VP of Finance, and he will continue his job as executive VP of the company's Bruker Daltonics subsidiary. Before working at Bruker, Monahan was a financial and accounting manager at Fisher Scientific, and he previously was an audit manager for PricewaterhouseCoopers.


The Integrated Biobank of Luxembourg has chosen Robert Hewitt to serve as its CEO. As head of IBBL, Hewitt will run the tissue storage and distribution initiative to support a worldwide network of cancer research. Hewitt, who has developed biobanks in England, Saudi Arabia, and in Singapore, where he is director of a repository at the National University of Singapore, will take on the new position in July.


Bioasis Technologies has hired Mark Godsy to help the company develop its overall strategy. Godsy is an entrepreneur who specializes in corporate development and venture capital, and he is a co-founder of ID Biomedical and Angiotech Pharmaceuticals.


Vermillion's VP and Chief Ccientific Officer, Eric Fung, has resigned from the company. Vermillion said in a filing with the US Securities and Exchange Commission that Fung left the company to pursue another opportunity and not because of any disagreement.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People in the News, a weekly roundup of industry comings and goings.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.